Pharmaceutical expenditure in Spain: cost and control

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Public Health

Background:

• Spanish government implemented cost-containment measures for pharmaceutical expenditures.
• Measures included price controls, drug reimbursement restrictions, increased cost-sharing, and expenditure budgets.

Purpose of the Study:

• To analyze the effectiveness of pharmaceutical cost-containment measures in Spain.
• To identify reasons for the persistent rise in pharmaceutical spending.

Main Methods:

• Analysis of pharmaceutical expenditure trends over 15 years.
• Evaluation of the impact of implemented cost-containment policies.

Main Results:

• Despite declining prices of older drugs, real pharmaceutical expenditures increased by 264%.
• Introduction of new, expensive drugs with limited therapeutic advantages is a primary driver of cost increases.
• Lack of demand-side measures, such as physician budgets and a robust generics market, hinders cost control.

Conclusions:

• Current cost-containment strategies in Spain have been largely ineffective in controlling pharmaceutical expenditures.
• The influx of high-cost, innovative drugs, coupled with insufficient demand-side management, necessitates a re-evaluation of pharmaceutical policy.